MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study
| Autor: | Mark A. Socinski, Nick Pavlakis, Alexey V. Salnikov, Nicola Steele, Jens Benn Sørensen, Martin Reck, Anna K. Nowak, Federica Grosso, David Planchard, Giovanni Luca Ceresoli, Natasha B. Leighl, Brett G.M. Hughes, T. Kitzing, Sanjay Popat, K. Pietzko, Silvia Novello, G.V. Scagliotti, Jürgen Braunger, Laurent Greillier, Thomas John, Julien Mazieres |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Cisplatin medicine.medical_specialty Lume Pleural mesothelioma business.industry 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Pemetrexed chemistry 030220 oncology & carcinogenesis Internal medicine medicine Biomarker (medicine) Nintedanib business medicine.drug |
| Zdroj: | Journal of Thoracic Oncology. 12:S1884 |
| ISSN: | 1556-0864 |
| DOI: | 10.1016/j.jtho.2017.09.636 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|